DK0675733T3 - Peptid-carbohydrat-konjugater, der genererer T-celleimmunitet - Google Patents

Peptid-carbohydrat-konjugater, der genererer T-celleimmunitet

Info

Publication number
DK0675733T3
DK0675733T3 DK93912042T DK93912042T DK0675733T3 DK 0675733 T3 DK0675733 T3 DK 0675733T3 DK 93912042 T DK93912042 T DK 93912042T DK 93912042 T DK93912042 T DK 93912042T DK 0675733 T3 DK0675733 T3 DK 0675733T3
Authority
DK
Denmark
Prior art keywords
carbohydrate
peptide
cell immunity
generating
carbohydrate conjugates
Prior art date
Application number
DK93912042T
Other languages
Danish (da)
English (en)
Inventor
Mikael Jondal
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9201338A external-priority patent/SE9201338D0/xx
Priority claimed from SE9202553A external-priority patent/SE9202553D0/xx
Priority claimed from SE9203897A external-priority patent/SE9203897D0/xx
Priority claimed from SE9301141A external-priority patent/SE9301141D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK0675733T3 publication Critical patent/DK0675733T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK93912042T 1992-04-28 1993-04-23 Peptid-carbohydrat-konjugater, der genererer T-celleimmunitet DK0675733T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE9201338A SE9201338D0 (sv) 1992-04-28 1992-04-28 New active compounds
SE9202553A SE9202553D0 (sv) 1992-09-07 1992-09-07 New active compounds ii
SE9203897A SE9203897D0 (sv) 1992-12-23 1992-12-23 New active compounds iii
SE9301141A SE9301141D0 (sv) 1993-04-06 1993-04-06 New active compounds iv
PCT/SE1993/000353 WO1993021948A1 (en) 1992-04-28 1993-04-23 Peptide-carbohydrate conjugates generating t-cell immunity

Publications (1)

Publication Number Publication Date
DK0675733T3 true DK0675733T3 (da) 2001-05-07

Family

ID=27484749

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93912042T DK0675733T3 (da) 1992-04-28 1993-04-23 Peptid-carbohydrat-konjugater, der genererer T-celleimmunitet

Country Status (19)

Country Link
US (2) US5807559A (de)
EP (1) EP0675733B1 (de)
JP (1) JPH07506358A (de)
CN (1) CN1096032A (de)
AT (1) ATE197903T1 (de)
AU (1) AU676679B2 (de)
CA (1) CA2134097A1 (de)
DE (1) DE69329735T2 (de)
DK (1) DK0675733T3 (de)
ES (1) ES2155070T3 (de)
GR (1) GR3035501T3 (de)
IL (1) IL105503A (de)
IS (1) IS4010A (de)
MA (1) MA22885A1 (de)
MY (1) MY108864A (de)
PT (1) PT675733E (de)
SI (1) SI9300223A (de)
TN (1) TNSN93045A1 (de)
WO (1) WO1993021948A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083929A (en) * 1991-05-06 2000-07-04 The Biomembrane Institute Extended type 1 chain glycosphingolipids as tumor-associated antigens
DE4436164A1 (de) * 1994-10-10 1996-04-11 Hoechst Ag Neue Kohlenhydratkonjugate als Inhibitoren der Zelladhäsion
US6548643B1 (en) 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
US6841543B1 (en) 1996-01-31 2005-01-11 President And Fellows Of Harvard College Methods of inhibiting production of T helper type 2 cytokines in human immune cells
US6218363B1 (en) * 1996-08-28 2001-04-17 Thomas Jefferson University MHC peptides and methods of use
WO1998015286A1 (en) * 1996-10-08 1998-04-16 La Jolla Institute For Allergy & Immunology Carbohydrate-specific cytolytic t cells
US20070237785A1 (en) * 1997-03-27 2007-10-11 Institut Pasteur Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
EP0969873B1 (de) * 1997-03-27 2006-06-07 Institut Pasteur Multiple,kohlenhydrathaltige glycopeptid-antigene, daraus entwickelte impfstoffe sowie deren verwendung
US7550146B2 (en) * 1997-04-16 2009-06-23 Sloan-Kettering Institute For Cancer Research Glycopeptide conjugates and uses thereof
CA2286798C (en) * 1997-04-16 2014-01-07 Sloan-Kettering Institute For Cancer Research Alpha-o-linked glycoconjugates with clustered(2,6)-st epitopes, methods of preparation and uses thereof
AUPO732997A0 (en) * 1997-06-12 1997-07-03 Csl Limited Ganglioside immunostimulating complexes and uses thereof
JP2002507577A (ja) * 1998-03-25 2002-03-12 スローン−ケッタリング インスティトュート フォア キャンサー リサーチ 三量体抗原性ｏ−結合複合糖ペプチド、その製造方法及びその使用
AU3456099A (en) 1998-03-31 1999-10-18 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
US7402307B2 (en) * 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
EP1073667A2 (de) * 1998-04-28 2001-02-07 Galenica Pharmaceuticals, Inc. Polysaccharid-antigen-konjugate
US20030091546A1 (en) * 1998-11-12 2003-05-15 Barber Jack R. Methods of suppressing immune response by gene therapy
US7824687B2 (en) 1999-08-20 2010-11-02 Sloan-Kettering Institute For Cancer Research Clustered multi-antigenic carbohydrate constructs, methods for their preparation, and uses thereof
DE60027905T2 (de) 1999-08-20 2007-05-10 Sloan-Kettering Institute For Cancer Research Glycokonjugate, glycoaminosäure, deren zwischenprodukte, und ihre verwendung
US7854934B2 (en) * 1999-08-20 2010-12-21 Sloan-Kettering Institute For Cancer Research Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof
DE10005275A1 (de) * 2000-02-07 2001-08-09 Bayer Ag Neuartige Glycokonjugate
US20030049253A1 (en) * 2001-08-08 2003-03-13 Li Frank Q. Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines
UA79952C2 (en) * 2001-12-10 2007-08-10 Kabulesh Mafatlal Khamar MYCOBACTERIUM w APPLICATIONS FOR CANCER TREATMENT
JP2007516157A (ja) * 2003-02-06 2007-06-21 トリペップ アクチ ボラゲット グリコシル化された抗原／抗体又はリガンド／受容体特異性交換体
WO2005077411A2 (en) * 2004-02-10 2005-08-25 Innate Pharma Composition and method for the treatment of carcinoma
CN101184780B (zh) 2005-05-05 2012-10-03 森馨香料公司 β-葡聚糖和甘露聚糖的制备
WO2007073486A2 (en) 2005-12-20 2007-06-28 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
EP2391635B1 (de) 2009-01-28 2017-04-26 Epimmune Inc. Pan-dr-bindende polypeptide und verwendungen davon
AU2011232435B2 (en) 2010-03-23 2016-01-28 Intrexon Corporation Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
EP2500033A1 (de) 2011-03-17 2012-09-19 Institut Pasteur Verfahren zur Herstellung mehrfacher Antigen-Glycopeptid-Kohlenhydratkonjugate
JP2014524796A (ja) 2011-06-28 2014-09-25 イノビオ ファーマシューティカルズ，インコーポレイティド 低侵襲表皮電気穿孔装置
EP2606897A1 (de) 2011-12-22 2013-06-26 Laboratorios Del. Dr. Esteve, S.A. Verfahren und Zusammensetzungen für die Behandlung von Krankheiten, die von eingehüllten Viren verursacht werden
CA3069527A1 (en) 2017-07-12 2019-01-17 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for treatment of cancers harboring an h3k27m mutation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2004744B (en) * 1977-09-28 1982-05-26 Sanderson A R Immonulogical preparations
CA1335883C (en) * 1986-07-08 1995-06-13 Bryan Michael Longenecker Enhancement of the cellular immune response
ATE109008T1 (de) * 1988-02-01 1994-08-15 Praxis Biolog Inc T-zellen-epitope als träger für einen konjugierten impfstoff.
JPH03504493A (ja) * 1988-02-12 1991-10-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 細胞性免疫の発生及び操作のための合成ペプチドの使用
US5229289A (en) * 1988-03-11 1993-07-20 The Biomembrane Institute Monoclonal antibodies and vaccine development directed to human cancer-associated antigens by immunization with animal and human and with synthetic carbohydrate-carrier conjugates
CA1337403C (en) * 1988-03-28 1995-10-24 Biomembrane Institute (The) Methods for the production of antibodies and induction of immune responses to tumor-associated gangliosides by immunization with ganglioside lactones
JPH04506662A (ja) * 1989-07-14 1992-11-19 アメリカン・サイアナミド・カンパニー 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー
WO1991003494A1 (en) * 1989-08-28 1991-03-21 Pierce Chemical Company Cationized carriers for immunogen production
GB8924438D0 (en) * 1989-10-31 1989-12-20 Hoffmann La Roche Vaccine composition
IT1237764B (it) * 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.

Also Published As

Publication number Publication date
JPH07506358A (ja) 1995-07-13
PT675733E (pt) 2001-05-31
SI9300223A (en) 1994-03-31
AU676679B2 (en) 1997-03-20
US5807559A (en) 1998-09-15
CN1096032A (zh) 1994-12-07
US6033669A (en) 2000-03-07
WO1993021948A1 (en) 1993-11-11
MA22885A1 (fr) 1993-12-31
IL105503A0 (en) 1993-08-18
MY108864A (en) 1996-11-30
TNSN93045A1 (fr) 1994-03-17
DE69329735T2 (de) 2001-08-02
CA2134097A1 (en) 1993-11-11
ES2155070T3 (es) 2001-05-01
IS4010A (is) 1993-10-29
EP0675733B1 (de) 2000-12-06
ATE197903T1 (de) 2000-12-15
DE69329735D1 (de) 2001-01-11
AU4274693A (en) 1993-11-29
GR3035501T3 (en) 2001-06-29
IL105503A (en) 1999-05-09
EP0675733A1 (de) 1995-10-11

Similar Documents

Publication Publication Date Title
DK0675733T3 (da) Peptid-carbohydrat-konjugater, der genererer T-celleimmunitet
BR9303469A (pt) Conjugado de interferon,composto,processo de preparacao de um conjugado de interferon,use e composicoes farmaceuticas
ES2056215T5 (es) Composiciones de detergentes.
EE200000378A (et) Adamantaani derivaadid
ATE244015T1 (de) Formulierungen fuer faktor ix
FI914607A (fi) Farmaceutisk blandning i gelform i en dispenserfoerpackning.
GR3026658T3 (en) Hydrazino-type radionuclide chelators having an n 3?s configuration
DE68906366D1 (en) Cd4-polypeptidderivate.
ES2078521T3 (es) Nuevos conjugados de proteina-polication.
SE8504945L (sv) Farmaceutiska kompositioner innehallande antracyklinglykosider
ATE126215T1 (de) Anti-entzündende 4-aminophenol-derivate.
DE69826684D1 (de) Kovalent gebundenes n,o-carboxymethylchitosan und seine verwendungen
DE69527805D1 (de) Chemische mittel
IT8920898A0 (it) Uso di sucralfato gel umido per il trattamento di ulcere del derma e come veicolo di farmaci ad attivita' topica.
HU9203649D0 (en) Method for producing inclusion compounds of nimesulide with cyclodextrines and pharmaceutical preparatives containing these compounds
AR016427A1 (es) CONJUGADOS uTILES PARA EL TRATAMIENTO DE CÁNCER DE PRoSTATA, Y UNA COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE.
JO1766B1 (en) Effective new compounds
TW332816B (en) Peptide and carbohydrate
NO307757B1 (no) Uretanholdige aminosteroidforbindelser, farmasøytisk preparat samt anvendelse
FI961339A (fi) Triaryylieteenijohdannaiset käytettäväksi hoidossa
IT8820245A0 (it) Palmitoil_fruttosio_1,6_difosfato, suo uso terapeutico e relativi metodi di preparazione.
FR2652266B1 (fr) Vaccin protecteur contre l'hemophilose porcine.
TH13666A (th) สารประกอบออกฤทธิ์ชนิดใหม่
ITVI950066A0 (it) Procedimento per la fabbricazione di pannelli per l'impiego nel setto-re del mobile, a basso costo e atossico
FI953708A0 (fi) Menetelmä terapeuttisesti aktiivisten makrosyklisten bifunktionaalisten kelaatinmuodostajien, niiden kompleksien sekä niiden vasta-ainekonjugaattien valmistamiseksi